Saragovi
Horacio U. Saragovi, Montreal CA
Patent application number | Description | Published |
---|---|---|
20120165271 | METHODS OF TREATING RETINITIS PIGMENTOSA - The present invention relates to methods of treating retinitis pigmentosa using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs useful in treating retinitis pigmentosa. | 06-28-2012 |
Horacio Uri Saragovi, Montreal CA
Patent application number | Description | Published |
---|---|---|
20130310404 | INHIBITORS OF P75 RECEPTOR AND THEIR USES - Novel p75 receptor antagonist compounds and compositions and uses thereof for the prevention and treatment of p75-associated disorders, such as neurodegenerative diseases, are described. | 11-21-2013 |
20140004119 | AGONISTIC ANTIBODIES TO TRKC RECEPTORS AND USES THEREOF | 01-02-2014 |
H. Uri Saragovi, Montreal CA
Patent application number | Description | Published |
---|---|---|
20080305103 | Intraocular pressure-regulated early genes and uses thereof - The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or α2 macgroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or α2 macgroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or α2 macgroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins. | 12-11-2008 |
20100048461 | METHODS OF USE OF TRK RECEPTOR MODULATORS - The present invention relates to methods of treating or preventing retinal ganglion cell (RGC) death and/or glaucoma using modulators of neurotrophic receptors that comprise β-turn peptidomimetic cyclic compounds or derivatives thereof. The neurotrophic receptor modulators can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat or prevent ocular hypertension, RGC death and/or glaucoma. | 02-25-2010 |
Uri H. Saragovi, Montreal CA
Patent application number | Description | Published |
---|---|---|
20110189093 | PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODIES AND ANTIGEN BINDING FRAGMENTS - Polypeptides, antibodies or antigen-binding fragments capable of binding to prostate specific membrane antigen (PSMA) are provided. These polypeptides, antibodies or antigen-binding fragments may be used for diagnostic and/or therapeutic purposes. | 08-04-2011 |
20120093719 | ANTIBODIES AGAINST PROSTATE SPECIFIC MEMBRANE ANTIGEN - Antibodies (Ab) and antigen binding fragments capable of binding to prostate specific membrane antigen and which may be used for diagnostic and therapeutic purposes are provided herein. Formulation anti-PSMA antibodies which are stable under extreme storage condition are also provided. | 04-19-2012 |